Bio-Path Holdings, Inc. · OTC:BPTH
Bio-Path — Investor Presentation (October 2017)
20 slides from Bio-Path's investor presentation, October 2017

Slide 1: Company Overview October 2017
Company Overview October 2017 “A new path in DNA-powered medicine” 1

Slide 2: Forward Looking Statements
Forward Looking Statements This Presentation contains forward-looking statements with respect to business conducted by Bio-Path Holdings, Inc. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will

Slide 3: IP and Financial Snapshot
IP and Financial Snapshot Intellectual Property • Original patents licensed from MD Anderson • New composition and methods of use patents filed to cover DNAbilize® technology, solely owned by Bio-Path extends protection for 20 years • Notice of allowance July 2017 Financial Snapshot • Ticker: NASDAQ

Slide 4: DNAbilize Technology Platform
DNAbilize® Technology Platform ✓ Enables the development and delivery of systemic intravenous DNA treatments for a broad spectrum of cancers as well as diseases outside of cancer ✓ DNAbilize® is a Platform Technology with the potential to treat a number of oncology targets and other diseases ➢ Only

Slide 5: Investment Highlights
Investment Highlights • Next generation DNA based therapeutics Broad Vision, Focused • Original technology licensed from The MD Anderson Cancer Center with Strategy significant improvements from Bio-Path • Lead candidate, prexigebersen, in Phase II for acute myeloid leukemia and Clinical Stage Pipel

Slide 6: DNAbilize Technology Profile: A Targeted Method for Treating Disease
DNAbilize® Technology Profile: A Targeted Method for Treating Disease ➢ Antisense - molecules that interfere with the process of producing proteins inside cells (RNAi) ➢ Does not use a toxic agent to kill cells, but blocks production of proteins ➢ Advantage of specificity because it targets the dise

Slide 7: Why Antisense DNA?
Why Antisense DNA? • Antisense DNA inhibits the production of only the protein of interest. The specificity of the treatment means less side effects for the patient • Antisense DNA blocks the problem protein from being made. Other therapeutics attempt to inhibit a protein already in circulation. Wit

Slide 8: DNAbilize Technology Summary
DNAbilize® Technology Summary Core of the technology is a combination of a stable DNA backbone and a neutral lipid (fat cell) delivery that mimics the cell membrane SAFE: No toxicity from the DNA or the lipid delivery, no blood clotting or liver toxicity SYSTEMIC: Allows for whole body distribution

Slide 9: Liposomal Drug Uptake by Cells
Liposomal Drug Uptake by Cells Inhibitory DNA incorporated into liposomes that resemble the cell membrane seamlessly merge with the cell, releasing the DNA drug into the cytoplasm Outside the diseased cell: Inside the diseased cell: Liposome in the blood stream Significant uptake of the carrying DNA

Slide 10: Clinical Pipeline
Clinical Pipeline Target Indications Preclinical IND Phase I Phase II Prexigebersen (BP1001) AML* Prexigebersen (BP1001) CML* Prexigebersen Solid (BP1001) tumors BP1002 (Liposomal Bcl2) Lymphoma DNAbilize™ Technology Ready to out-license *Prexigebersen (BP1001) has received orphan drug designation f

Slide 11: Continuing Improvements in Product Manufacturing and Design
Continuing Improvements in Product Manufacturing and Design ➢ Through our dose-escalating Phase 1 trial we upgraded our supplier base with the goal of increased capability and capacity ➢ Several test batches have confirmed the potency of our currently manufactured drug product in AML cells. ➢ Identi

Slide 12: Summary of Phase I Monotherapy Clinical Trial Results for Prexigebersen
Summary of Phase I Monotherapy Clinical Trial Results for Prexigebersen ➢ Target of drug is a protein called Grb2, important in growth and proliferation of cancer cells ➢ Phase I trial for AML, CML, & MDS patients refractory or resistant to current therapies ➢ Patients averaged 6 prior therapies ➢ D

Slide 13: Safety Segment Phase II Prexigebersen + LDAC Combination Therapy Results
Safety Segment Phase II Prexigebersen + LDAC Combination Therapy Results ➢ Low Dose Ara C (LDAC) is the current frontline treatment for elderly AML ➢ The safety trial for the combination of LDAC + prexigebersen was evaluated in relapsed AML patients, average age 75 years old ➢ 3 evaluable patients i

Slide 14: Ongoing Phase II Efficacy Trial Design for AML Prexigebersen Combination Therapy
Ongoing Phase II Efficacy Trial Design for AML Prexigebersen Combination Therapy • Safety segment completed, demonstrated no negative synergies using prexigebersen together with frontline therapy, low dose chemotherapy (LDAC) – Treatment of newly diagnosed AML patients who are fragile – Efficacy tri

Slide 15: Advances in the CML Program
Advances in the CML Program Presentation at the December 2016 American Society of Hematology Annual Meeting • BP1001, a Novel Therapeutic for Chronic Myelogenous Leukemia • Prexigebersen (BP1001) decreased the proliferation of Gleevec® (imatinib)-resistant CML cells in a dose-dependent manner • Prex

Slide 16: Preclinical Pipeline
Preclinical Pipeline Validating DNAbilize™ with Key Opinion Leaders: • Establishing prexigebersen in triple negative and inflammatory breast cancer and advanced ovarian cancer with the MD Anderson Cancer Center – Advances in liposome properties enhancing solid tumor outcomes • Developing clinical an

Slide 17: Achievements and Upcoming Milestones
Achievements and Upcoming Milestones Enrolling and treating patients in Value propositions being advanced: prexigebersen Phase II efficacy trial for • Enrollment of first 19 patients in Phase II AML with an interim analysis to be completed with potential for switch to registration trial Safety s

Slide 18: Leadership
Leadership Peter Nielsen Co-Founder, President, Chief Executive Officer and Chief Financial Officer • Officer and Director since founding Company in 2007 • Manufacturing development and evolution of engineered product design William Hahne, M.D. Vice President of Clinical Research • Medical consultan

Slide 19: Scientific Advisory Board
Scientific Advisory Board Jorge Cortes, M.D. Chairman • M.D. from la Facultad de Medicina, Universidad Nacional Autónoma de México • Jane and John Justin Distinguished Chair in Leukemia Research, Chief of the AML and CML sections, and Deputy Chair of the Department of Leukemia at The University of T

Slide 20: Competitors with DNA/RNA Therapeutics
Competitors with DNA/RNA Therapeutics Company Bio-Path Ionis Alnylam Dicerna Drug DNA DNA siRNA siRNA Delivery Uncharged lipids None Sugar Sugar Blood clotting Safety Non-toxic Liver toxicity Liver toxicity toxicity Symbol BPTH IONS ALNY DRNA Share price $0.41 $52.93 $121.07 $6.27 Market cap $50 M $
Source: Internet Archive copy of biopathholdings.com
More decks from Bio-Path Holdings, Inc.
Investor Presentation (May 2022)12 slides · May 2022
Investor Presentation (January 2022)17 slides · January 2022
Investor Presentation (March 2021)17 slides · March 2021
Shareholder Meeting (December 2020)16 slides · Dec 21, 2020
Investor Presentation (May 2019)23 slides · May 2019
Investor Presentation (July 2017)22 slides · July 2017